Large owner Millennium Management Llc bought $141,364 worth of shares (4,215 units at $33.54) and sold $538,114 worth of shares (17,076 units at $31.51) (SEC Form 4)
$SNSE
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | ||||||||||||||||
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
(Country) | 2. Issuer Name and Ticker or Trading Symbol
Sensei Biotherapeutics, Inc. [ SNSE ] | 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| |||||||||||||||||||||||||
| 2a. Foreign Trading Symbol
| |||||||||||||||||||||||||||
| 3. Date of Earliest Transaction
(Month/Day/Year) 04/02/2026 | 6. Individual or Joint/Group Filing (Check Applicable Line)
| ||||||||||||||||||||||||||
| 4. If Amendment, Date of Original Filed
(Month/Day/Year) |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock | 04/02/2026 | P | 26 | A | $33.4704(1) | 144,974(2) | I | See Footnote(3) | ||
| Common Stock | 04/02/2026 | P | 1,276 | A | $34.7524(4) | 144,974(2) | I | See Footnote(3) | ||
| Common Stock | 04/02/2026 | P | 701 | A | $35.5472(5) | 144,974(2) | I | See Footnote(3) | ||
| Common Stock | 04/02/2026 | S | 3,099 | D | $30.8638(6) | 144,974(2) | I | See Footnote(3) | ||
| Common Stock | 04/02/2026 | S | 1,265 | D | $31.751(7) | 144,974(2) | I | See Footnote(3) | ||
| Common Stock | 04/02/2026 | S | 1,794 | D | $32.6041(8) | 144,974(2) | I | See Footnote(3) | ||
| Common Stock | 04/02/2026 | S | 374 | D | $33.347(9) | 144,974(2) | I | See Footnote(3) | ||
| Common Stock | 04/02/2026 | S | 1,134 | D | $34.8007(10) | 144,974(2) | I | See Footnote(3) | ||
| Common Stock | 04/06/2026 | P | 1,104 | A | $31.02(11) | 141,029(2) | I | See Footnote(3) | ||
| Common Stock | 04/06/2026 | S | 1,214 | D | $31.0227(12) | 141,029(2) | I | See Footnote(3) | ||
| Common Stock | 04/06/2026 | S | 45 | D | $31.9628(13) | 141,029(2) | I | See Footnote(3) | ||
| Common Stock | 04/07/2026 | P | 1,108 | A | $33.38(14) | 133,986(2) | I | See Footnote(3) | ||
| Common Stock | 04/07/2026 | S | 2,115 | D | $28.9417(15) | 133,986(2) | I | See Footnote(3) | ||
| Common Stock | 04/07/2026 | S | 205 | D | $29.7146(16) | 133,986(2) | I | See Footnote(3) | ||
| Common Stock | 04/07/2026 | S | 4,423 | D | $31.3843(17) | 133,986(2) | I | See Footnote(3) | ||
| Common Stock | 04/07/2026 | S | 300 | D | $32.2467(18) | 133,986(2) | I | See Footnote(3) | ||
| Common Stock | 04/07/2026 | S | 1,108 | D | $33.38(19) | 133,986(2) | I | See Footnote(3) | ||
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||||||
| Explanation of Responses: |
| 1. Represents volume-weighted average price ("VWAP") of purchases of 26 shares of common stock ("Common Stock"), par value $0.0001 per share, of Sensei Biotherapeutics, Inc. (the "Company") on April 2, 2026 at prices ranging from $32.90 to $33.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting persons will provide full information regarding the number of shares purchased or sold by the reporting person at each separate price within each range represented by a VWAP disclosed herein. |
| 2. In each case, the number of shares of the Company's Common Stock disclosed in column 5 is the number of shares of the Company's Common Stock beneficially owned by Millennium Management LLC at the conclusion of the transactions on the date disclosed in the corresponding entry in column 2. |
| 3. The transactions in the Company's Common Stock reported herein were made by ICS Opportunities II LLC or other trading entities, in each case subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC (the managing member of Millennium Management LLC) and Israel A. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). Each reporting person disclaims beneficial ownership of the shares of the Company's Common Stock disclosed herein except to the extent of such reporting person's pecuniary interest therein, if any. |
| 4. Represents VWAP of purchases of 1,276 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $33.97 to $34.90. |
| 5. Represents VWAP of purchases of 701 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $35.4481 to $35.91. |
| 6. Represents VWAP of sales of 3,099 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $30.1332 to $31.1212. |
| 7. Represents VWAP of sales of 1,265 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $31.21 to $32.15. |
| 8. Represents VWAP of sales of 1,794 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $32.22 to $33.1251. |
| 9. Represents VWAP of sales of 374 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $33.23 to $33.45. |
| 10. Represents VWAP of sales of 1,134 shares of the Company's Common Stock on April 2, 2026 at prices ranging from $34.40 to $35.25. |
| 11. Represents purchases of 1,104 shares of the Company's Common Stock on April 6, 2026 at $31.02 per share. |
| 12. Represents VWAP of sales of 1,214 shares of the Company's Common Stock on April 6, 2026 at prices ranging from $30.64 to $31.345. |
| 13. Represents VWAP of sales of 45 shares of the Company's Common Stock on April 6, 2026 at prices ranging from $31.80 to $32.17. |
| 14. Represents VWAP of purchases of 1,108 shares of the Company's Common Stock on April 7, 2026 at $33.38 per share. |
| 15. Represents VWAP of sales of 2,115 shares of the Company's Common Stock on April 7, 2026 at prices ranging from $28.5071 to $29.3167. |
| 16. Represents VWAP of sales of 205 shares of the Company's Common Stock on April 7, 2026 at prices ranging from $29.695 to $30.50. |
| 17. Represents VWAP of sales of 4,423 shares of the Company's Common Stock on April 7, 2026 at prices ranging from $30.9852 to $31.813. |
| 18. Represents VWAP of sales of 300 shares of the Company's Common Stock on April 7, 2026 at prices ranging from $32.0625 to $32.615. |
| 19. Represents sales of 1,108 shares of the Company's Common Stock on April 7, 2026 at $33.38 per share. |
| Remarks: |
| Assuming, without conceding, the application of Section 16(b) of the Securities Exchange Act of 1934, the reporting persons have disgorged to the Company all amounts that could be deemed profit realized by them from the transactions in the Company's Common Stock reported on this Form 4 and the other two statements on Form 4 filed by Millennium Management LLC on the same date. |
| MILLENNIUM MANAGEMENT LLC: By: /s/ Gil Raviv, Global General Counsel | 05/14/2026 | |
| ICS OPPORTUNITIES II LLC, By: Millennium Management LLC, its Investment Manager: By: /s/ Gil Raviv, Global General Counsel | 05/14/2026 | |
| MILLENNIUM GROUP MANAGEMENT LLC: By: /s/ Gil Raviv, Global General Counsel | 05/14/2026 | |
| /s/ Israel A. Englander | 05/14/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
| * Form 4: SEC 1474 (03-26) | ||